Associated Papers
Real-world use of and clinical outcomes with dacomitinib as first-line therapy in Asian patients with EGFR mutation-positive locally advanced or metastatic non-small cell lung cancer: Final analysis of the ARIA study.
Wu L et al.
Lung Cancer (amsterdam, Netherlands), 2026
EGFR Activation and Conformational "Convergence": An Emerging Allosteric Model From Cancer Mutations.
Orellana L
Journal of Molecular Biology, 2025
AKT1 Functional Polymorphism (rs2494750) Influences Clinical Outcomes in Patients With Advanced Lung Cancer Treated With EGFR Inhibitors.
Choi SH et al.
Journal of Korean Medical Science, 2025
Quantitative Protein Expression of Antibody-Drug Conjugate Targets in EGFR Mutated and Wild-type Non-Small Cell Lung Cancer.
Trontzas IP et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research, 2025
Prognostic and predictive biomarkers with therapeutic targets in nonsmall-cell lung cancer: A 2023 update on current development, evidence, and recommendation.
Chung C et al.
Journal of Oncology Pharmacy Practice : Official Publication of the International Society of Oncology Pharmacy Practitioners, 2025
Molecular characterization of Chinese patients with small bowel adenocarcinoma.
Jin B et al.
Clinical & Translational Oncology : Official Publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico, 2024
A Phase II trial of alternating osimertinib and gefitinib therapy in advanced EGFR-T790M positive non-small cell lung cancer: OSCILLATE.
Tan L et al.
Nature Communications, 2024
Clinical Impact of Genomic and Pathway Alterations in Stage I EGFR-Mutant Lung Adenocarcinoma.
Lee JS et al.
Cancer Research and Treatment, 2024
Alternating Therapy With Osimertinib and Afatinib Blockades EGFR Secondary Mutation in EGFR-Mutant Lung Cancer: A Single-Arm Phase II Trial.
Yonesaka K et al.
Clinical Lung Cancer, 2023
ARID1A deficiency reverses the response to anti-PD(L)1 therapy in EGFR-mutant lung adenocarcinoma by enhancing autophagy-inhibited type I interferon production.
Sun D et al.
Cell Communication and Signaling : Ccs, 2022
Treatment Strategies for Non-Small Cell Lung Cancer Harboring Common and Uncommon EGFR Mutations: Drug Sensitivity Based on Exon Classification, and Structure-Function Analysis.
Kitadai R et al.
Cancers, 2022
The clinicopathological and molecular characteristics of resected EGFR-mutant lung adenocarcinoma.
Zhou W et al.
Cancer Medicine, 2022
Genomic characteristics of driver genes in Chinese patients with non-small cell lung cancer.
Si X et al.
Thoracic Cancer, 2021
Tackling Drug Resistance in EGFR Exon 20 Insertion Mutant Lung Cancer.
Pacini L et al.
Pharmacogenomics and Personalized Medicine, 2021
The Predictive Values of Advanced Non-Small Cell Lung Cancer Patients Harboring Uncommon EGFR Mutations-The Mutation Patterns, Use of Different Generations of EGFR-TKIs, and Concurrent Genetic Alterations.
Tan J et al.
Frontiers in Oncology, 2021
Expression Profiling of Driver Genes in Female Never-smokers With Non-adenocarcinoma Non-small-cell Lung Cancer in China.
Zhao Y et al.
Clinical Lung Cancer, 2020
Making the case for EGFR TKI sequencing in EGFR mutation-positive NSCLC: a GioTag study US patient analysis.
Feinberg B et al.
Future Oncology (london, England), 2020
ERBB3 mutations in cancer: biological aspects, prevalence and therapeutics.
Kiavue N et al.
Oncogene, 2020
Trastuzumab and paclitaxel in patients with EGFR mutated NSCLC that express HER2 after progression on EGFR TKI treatment.
de Langen AJ et al.
British Journal of Cancer, 2018
Optimizing outcomes in EGFR mutation-positive NSCLC: which tyrosine kinase inhibitor and when?
Girard N
Future Oncology (london, England), 2018
Simultaneous identification of clinically relevant single nucleotide variants, copy number alterations and gene fusions in solid tumors by targeted next-generation sequencing.
Oliveira DM et al.
Oncotarget, 2018
Outcomes of research biopsies in clinical trials of EGFR mutation-positive non-small cell lung cancer patients pretreated with EGFR-tyrosine kinase inhibitors.
Liao BC et al.
Journal of the Formosan Medical Association = Taiwan Yi Zhi, 2018
Validation of the digital PCR system in tyrosine kinase inhibitor-resistant EGFR mutant non-small-cell lung cancer.
Masago K et al.
Pathology International, 2018
Frequency, impact and a preclinical study of novel ERBB gene family mutations in HER2-positive breast cancer.
Elster N et al.
Therapeutic Advances in Medical Oncology, 2018
Detection of epidermal growth factor receptor gene T790M mutation in cytology samples using the cobas® EGFR mutation test.
Satouchi M et al.
Lung Cancer (amsterdam, Netherlands), 2017
Osimertinib in patients with advanced epidermal growth factor receptor T790M mutation-positive non-small cell lung cancer: rationale, evidence and place in therapy.
Ricciuti B et al.
Therapeutic Advances in Medical Oncology, 2017
Mutations of the Epidermal Growth Factor Receptor Gene in Triple-Negative Breast Cancer.
Kim A et al.
Journal of Breast Cancer, 2017
HER2 overexpression reverses the relative resistance of EGFR-mutant H1975 cell line to gefitinib.
Xu J et al.
Oncology Letters, 2016
Not all epidermal growth factor receptor mutations in lung cancer are created equal: Perspectives for individualized treatment strategy.
Kobayashi Y et al.
Cancer Science, 2016
Protein-structure-guided discovery of functional mutations across 19 cancer types.
Niu B et al.
Nature Genetics, 2016
Cytotoxicity of allitinib, an irreversible anti-EGFR agent, in a large panel of human cancer-derived cell lines: KRAS mutation status as a predictive biomarker.
Silva-Oliveira RJ et al.
Cellular Oncology (dordrecht, Netherlands), 2016
EGFR-activating mutations, DNA copy number abundance of ErbB family, and prognosis in lung adenocarcinoma.
Chen HY et al.
Oncotarget, 2016
Identification of a novel HER3 activating mutation homologous to EGFR-L858R in lung cancer.
Umelo I et al.
Oncotarget, 2016
Mechanisms of resistance to EGFR-targeted drugs: lung cancer.
Morgillo F et al.
Esmo Open, 2016
Phase I study of the HER3-targeted antibody patritumab (U3-1287) combined with erlotinib in Japanese patients with non-small cell lung cancer.
Nishio M et al.
Lung Cancer (amsterdam, Netherlands), 2015
ERBB3-independent activation of the PI3K pathway in EGFR-mutant lung adenocarcinomas.
Song X et al.
Cancer Research, 2015
Known and putative mechanisms of resistance to EGFR targeted therapies in NSCLC patients with EGFR mutations-a review.
Stewart EL et al.
Translational Lung Cancer Research, 2015
SNPs in the transforming growth factor-β pathway as predictors of outcome in advanced lung adenocarcinoma with EGFR mutations treated with gefitinib.
Zhang L et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology, 2014
The ErbB/HER family of protein-tyrosine kinases and cancer.
Roskoski R
Pharmacological Research, 2014
The quest to overcome resistance to EGFR-targeted therapies in cancer.
Chong CR et al.
Nature Medicine, 2013
Sensitivity and kinase activity of epidermal growth factor receptor (EGFR) exon 19 and others to EGFR-tyrosine kinase inhibitors.
Furuyama K et al.
Cancer Science, 2013
Analytic performance studies and clinical reproducibility of a real-time PCR assay for the detection of epidermal growth factor receptor gene mutations in formalin-fixed paraffin-embedded tissue specimens of non-small cell lung cancer.
O'Donnell P et al.
Bmc Cancer, 2013
DNA-Mutation Inventory to Refine and Enhance Cancer Treatment (DIRECT): a catalog of clinically relevant cancer mutations to enable genome-directed anticancer therapy.
Yeh P et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research, 2013
[EGFR mutation status in Uighur lung adenocarcinoma patients].
Shan L et al.
Zhongguo Fei Ai Za Zhi = Chinese Journal of Lung Cancer, 2013
Phase I and pharmacokinetic study of dacomitinib (PF-00299804), an oral irreversible, small molecule inhibitor of human epidermal growth factor receptor-1, -2, and -4 tyrosine kinases, in Japanese patients with advanced solid tumors.
Takahashi T et al.
Investigational New Drugs, 2012
Combined therapy with mutant-selective EGFR inhibitor and Met kinase inhibitor for overcoming erlotinib resistance in EGFR-mutant lung cancer.
Nakagawa T et al.
Molecular Cancer Therapeutics, 2012
Functional mutation analysis of EGFR family genes and corresponding lymph node metastases in head and neck squamous cell carcinoma.
Hama T et al.
Clinical & Experimental Metastasis, 2012
Mutations of the epidermal growth factor receptor gene in NSCLC patients.
Han B et al.
Oncology Letters, 2011
The Pharmacogenetic Rescue of Side-Lined Anticancer Drugs to the Front-Line: Gefitinib as a Case Example.
Li-Wan-Po A et al.
The Annals of Pharmacotherapy, 2011
Correlation of F-18 fluorodeoxyglucose-positron emission tomography maximal standardized uptake value and EGFR mutations in advanced lung adenocarcinoma.
Huang CT et al.
Medical Oncology (northwood, London, England), 2010